FDA ·
FDA's 2026 enforcement priorities, as articulated in public Commissioner statements and Agency guidance, include compounded drug oversight (with GLP-1s explicitly named), unapproved new drug enforcement, API supply chain integrity, and combating counterfeits. The agency has emphasized a shift toward data-driven enforcement using inspection scheduling algorithms and manufacturer risk scoring. Resource constraints remain a real limitation; FDA has publicly acknowledged staffing limits on the number of compounding pharmacy inspections that can be conducted annually. These constraints are a recurring theme in congressional oversight hearings throughout early 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.